Duchenne and becker muscular dystrophies

Neurologic Clinics

Volumn 32, Issue 3, 2014, Pages 671-688

  Flanigan, Kevin M ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Becker muscular dystrophy; Duchenne muscular dystrophy; Dystrophin; Exon skipping

Indexed keywords

2' O METHYLPHOSPHOROTHIOATE; ANGIOTENSIN RECEPTOR ANTAGONIST; COMPLEMENTARY DNA; CORTICOSTEROID; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; OSTEOPONTIN; PARVOVIRUS VECTOR; PHOSPHOROTHIOIC ACID DERIVATIVE; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; BECKER MUSCULAR DYSTROPHY; BLOOD CHEMISTRY; CARDIOMYOPATHY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FAMILY HISTORY; GAIT DISORDER; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPOVENTILATION; LABORATORY TEST; MOLECULAR DIAGNOSTICS; MOTOR PERFORMANCE; MUSCLE BIOPSY; MUSCLE FUNCTION; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL MEDICINE; PHYSIOTHERAPY; PRIORITY JOURNAL; PULMONARY REHABILITATION; RATING SCALE; REVIEW; RISK FACTOR; SCOLIOSIS; SEQUENCE ANALYSIS; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; VIRAL GENE DELIVERY SYSTEM; GENETICS; MALE; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE;

DYSTROPHIN; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84904367458     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.05.002     Document Type: Review

References (144)

1. Emery A.E. Population frequencies of neuromuscular diseases-II. Amyotrophic lateral sclerosis (motor neurone disease). Neuromuscul Disord 1991, 1(5):323-325.
2. Mendell J.R., Shilling C., Leslie N.D., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012, 71(3):304-313.
3. Bushby K.M., Thambyayah M., Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet 1991, 337(8748):1022-1024.
4. Monaco A.P., Bertelson C.J., Liechti-Gallati S., et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2(1):90-95.
5. Connolly A.M., Florence J.M., Cradock M.M., et al. Motor and cognitive assessment of infants and young boys with duchenne muscular dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord 2013, 23(7):529-539.
6. Noritz G.H., Murphy N.A., Neuromotor Screening Expert Panel Motor delays: early identification and evaluation. Pediatrics 2013, 131(6):e2016-e2027.
7. Cyrulnik S.E., Fee R.J., De Vivo D.C., et al. Delayed developmental language milestones in children with Duchenne's muscular dystrophy. JPediatr 2007, 150(5):474-478.
8. Cotton S.M., Voudouris N.J., Greenwood K.M. Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis. Dev Med Child Neurol 2005, 47(4):257-265.
9. Cotton S., Voudouris N.J., Greenwood K.M. Intelligence and duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol 2001, 43(7):497-501.
10. Hendriksen J.G., Vles J.S. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. JChild Neurol 2008, 23(5):477-481.
11. Duchenne G.B. Récherches sur la paralysie musculaire pseudohypertrophique, ou paralysie myosclérosique. Arch Gén Méd 1868, 11(5).
12. Kornegay J.N., Childers M.K., Bogan D.J., et al. The paradox of muscle hypertrophy in muscular dystrophy. Phys Med Rehabil Clin N Am 2012, 23(1):149-172. xii.
13. Ciafaloni E., Fox D.J., Pandya S., et al. Delayed diagnosis in duchenne musculardystrophy: data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet). JPediatr 2009, 155(3):380-385.
14. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983, 6(2):91-103.
15. Brooke M.H., Griggs R.C., Mendell J.R., et al. The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials. Trans Am Neurol Assoc 1981, 106:195-199.
16. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(Suppl 5):S70-S92.
17. Nicholson L.V., Johnson M.A., Bushby K.M., et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. JMed Genet 1993, 30(9):728-736.
18. Tangsrud S., Petersen I.L., Lodrup Carlsen K.C., et al. Lung function in children with Duchenne's muscular dystrophy. Respir Med 2001, 95(11):898-903.
19. Becker P.E. Dystrophia Musculorum Progressiva. Eine genetische und klinische Untersuchung der Muskeldystrophien 1953, Thieme, Stuttgart (Germany).
20. Becker P.E. Two families of benign sex-linked recessive muscular dystrophy. Rev Can Biol 1962, 21:551-566.
21. Bushby K.M., Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. JNeurol 1993, 240(2):98-104.
22. Flanigan K.M., Dunn D.M., von Niederhausern A., et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009, 30(12):1657-1666.
23. Yazaki M., Yoshida K., Nakamura A., et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999, 42(3):145-149.
24. Heald A., Anderson L.V., Bushby K.M., et al. Becker muscular dystrophy with onset after 60 years. Neurology 1994, 44(12):2388-2390.
25. Sunohara N., Arahata K., Hoffman E.P., et al. Quadriceps myopathy: forme fruste of Becker muscular dystrophy. Ann Neurol 1990, 28(5):634-639.
26. Bushby K.M., Cleghorn N.J., Curtis A., et al. Identification of a mutation in the promoter region of the dystrophin gene in a patient with atypical Becker muscular dystrophy. Hum Genet 1991, 88(2):195-199.
27. Minetti C., Tanji K., Chang H.W., et al. Dystrophinopathy in two young boys withexercise-induced cramps and myoglobinuria. Eur J Pediatr 1993, 152(10):848-851.
28. Melis M.A., Cau M., Muntoni F., et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol 1998, 2(5):255-261.
29. Flanigan K.M., Dunn D.M., von Niederhausern A., et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 2009, 19(11):743-748.
30. Young H.K., Barton B.A., Waisbren S., et al. Cognitive and psychological profile ofmales with Becker muscular dystrophy. JChild Neurol 2008, 23(2):155-162.
31. North K.N., Miller G., Iannaccone S.T., et al. Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy. Neurology 1996, 46(2):461-465.
32. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. NEngl J Med 1989, 320(24):1592-1597.
33. Lerario A., Bonfiglio S., Sormani M., et al. Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurol 2012, 12:91.
34. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013, 48(3):357-368.
35. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013, 48(3):343-356.
36. Vuillerot C., Girardot F., Payan C., et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol 2010, 52(1):60-65.
37. Mazzone E.S., Messina S., Vasco G., et al. Reliability of the north star ambulatory assessment in a multicentric setting. Neuromuscul Disord 2009, 19(7):458-461.
38. Mazzone E., Vasco G., Sormani M.P., et al. Functional changes in duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011, 77(3):250-256.
39. Zatz M., Rapaport D., Vainzof M., et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. JNeurol Sci 1991, 102(2):190-196.
40. Thakker P.B., Sharma A. Becker muscular dystrophy: an unusual presentation. Arch Dis Child 1993, 69(1):158-159.
41. Doriguzzi C., Palmucci L., Mongini T., et al. Exercise intolerance and recurrent myoglobinuria as the only expression of Xp21 Becker type muscular dystrophy. JNeurol 1993, 240(5):269-271.
42. Shoji T., Nishikawa Y., Saito N., et al. Acase of Becker muscular dystrophy andmassive myoglobinuria with minimal renal manifestations. Nephrol Dial Transplant 1998, 13(3):759-760.
43. Drummond L.M. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Arch Dis Child 1979, 54(5):362-366.
44. Pearce J.M., Pennington R.J., Walton J.N. Serum enzyme studies in muscle disease. III. Serum creatine kinase activity in relatives of patients with the duchenne type of muscular dystrophy. JNeurol Neurosurg Psychiatry 1964, 27:181-185.
45. Drousiotou A., Ioannou P., Georgiou T., et al. Neonatal screening for duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998, 2(1):55-60.
46. Bradley D.M., Parsons E.P., Clarke A.J. Experience with screening newborns for duchenne muscular dystrophy in Wales. BMJ 1993, 306(6874):357-360.
47. Plauchu H., Dorche C., Cordier M.P., et al. Duchenne muscular dystrophy: neonatal screening and prenatal diagnosis. Lancet 1989, 1(8639):669.
48. Skinner R., Emery A.E., Scheuerbrandt G., et al. Feasibility of neonatal screening for duchenne muscular dystrophy. JMed Genet 1982, 19(1):1-3.
49. Morse R.P., Rosman N.P. Diagnosis of occult muscular dystrophy: importance of the "chance" finding of elevated serum aminotransferase activities. JPediatr 1993, 122(2):254-256.
50. Zamora S., Adams C., Butzner J.D., et al. Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. Can J Gastroenterol 1996, 10(6):389-393.
51. Vajro P., Del Giudice E., Veropalumbo C. Muscular dystrophy revealed by incidentally discovered elevated aminotransferase levels. JPediatr 2010, 156(4):689.
52. Veropalumbo C., Del Giudice E., Esposito G., et al. Aminotransferases and muscular diseases: a disregarded lesson. Case reports and review of the literature. JPaediatr Child Health 2012, 48(10):886-890.
53. McMillan H.J., Gregas M., Darras B.T., et al. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics 2011, 127(1):e132-e136.
54. Rosales X.Q., Chu M.L., Shilling C., et al. Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage. JChild Neurol 2008, 23(7):748-751.
55. Viollet L., Gailey S., Thornton D.J., et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 2009, 40(3):438-442.
56. Dent K.M., Dunn D., von Niederhausern A.C., et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005, 134:295-298.
57. Yan J., Feng J., Buzin C.H., et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). Hum Mutat 2004, 23(2):203-204.
58. Gurvich O.L., Tuohy T.M., Howard M.T., et al. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol 2008, 63(1):81-89.
59. Tuffery-Giraud S., Saquet C., Chambert S., et al. Pseudoexon activation in the DMD gene as a novel mechanism for Becker muscular dystrophy. Hum Mutat 2003, 21(6):608-614.
60. Arechavala-Gomeza V., Kinali M., Feng L., et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010, 20(5):295-301.
61. Nicholson L.V., Davison K., Johnson M.A., et al. Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. JNeurol Sci 1989, 94(1-3):137-146.
62. Nicholson L.V., Johnson M.A., Gardner Medwin D., et al. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol 1990, 80(3):239-250.
63. Klein C.J., Coovert D.D., Bulman D.E., et al. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992, 50(5):950-959.
64. Fanin M., Danieli G.A., Vitiello L., et al. Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul Disord 1992, 2(1):41-45.
65. Burrow K.L., Coovert D.D., Klein C.J., et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology 1991, 41(5):661-666.
66. Hoffman E.P., Kunkel L.M., Angelini C., et al. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989, 39(8):1011-1017.
67. Taylor L.E., Kaminoh Y.J., Rodesch C.K., et al. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens. Neuropathol Appl Neurobiol 2012, 38(6):591-601.
68. Tuffery-Giraud S., Beroud C., Leturcq F., et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009, 30(6):934-945.
69. Beggs A.H., Koenig M., Boyce F.M., et al. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990, 86(1):45-48.
70. Chamberlain J.S., Gibbs R.A., Ranier J.E., et al. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. PCR protocols: a guide to methods and applications 1990, 272-281. Academic Press, San Francisco (CA). M.A. Innis, D.H. Gelfand, J.J. Sninsky (Eds.).
71. Janssen B., Hartmann C., Scholz V., et al. MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls. Neurogenetics 2005, 6:29-35.
72. Schwartz M., Duno M. Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genet Test 2004, 8(4):361-367.
73. del Gaudio D., Yang Y., Boggs B.A., et al. Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization. Hum Mutat 2008, 29(9):1100-1107.
74. Hegde M.R., Chin E.L., Mulle J.G., et al. Microarray-based mutation detection in the dystrophin gene. Hum Mutat 2008, 29(9):1091-1099.
75. Saillour Y., Cossee M., Leturcq F., et al. Detection of exonic copy-number changes using a highly efficient oligonucleotide-based comparative genomic hybridization-array method. Hum Mutat 2008, 29(9):1083-1090.
76. Madden H.R., Fletcher S., Davis M.R., et al. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Hum Mutat 2009, 30(1):22-28.
77. Flanigan K.M., Dunn D., Larsen C.A., et al. Becker muscular dystrophy due to an inversion of exons 23 and 24 of the DMD gene. Muscle Nerve 2011, 44(5):822-825.
78. Cagliani R., Sironi M., Ciafaloni E., et al. An intragenic deletion/inversion event in the DMD gene determines a novel exon creation and results in a BMD phenotype. Hum Genet 2004, 115(1):13-18.
79. Bettecken T., Muller C.R. Identification of a 220-kb insertion into the Duchenne gene in a family with an atypical course of muscular dystrophy. Genomics 1989, 4(4):592-596.
80. Grimm T., Muller B., Muller C.R., et al. Theoretical considerations on germline mosaicism in Duchenne muscular dystrophy. JMed Genet 1990, 27(11):683-687.
81. Barbujani G., Russo A., Danieli G.A., et al. Segregation analysis of 1885 DMD families: significant departure from the expected proportion of sporadic cases. Hum Genet 1990, 84(6):522-526.
82. Arpan I., Forbes S.C., Lott D.J., et al. T(2) mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed 2013, 26(3):320-328.
83. Forbes S.C., Walter G.A., Rooney W.D., et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology 2013, 269(1):198-207.
84. Willcocks R.J., Arpan I.A., Forbes S.C., et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 2014, 24(5):393-401.
85. Hollingsworth K.G., Garrood P., Eagle M., et al. Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months. Muscle Nerve 2013, 48(4):586-588.
86. Matsumura K., Tome F.M., Collin H., et al. Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 1992, 359(6393):320-322.
87. Matsumura K., Campbell K.P. Deficiency of dystrophin-associated proteins: acommon mechanism leading to muscle cell necrosis in severe childhood muscular dystrophies. Neuromuscul Disord 1993, 3(2):109-118.
88. Brockington M., Blake D.J., Prandini P., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001, 69(6):1198-1209.
89. Schwartz M., Hertz J.M., Sveen M.L., et al. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 2005, 64(9):1635-1637.
90. Flanigan K.M., Dunn D.M., von Niederhausern A., et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 2011, 32(3):299-308.
91. Ginjaar I.B., Kneppers A.L., v d Meulen J.D., et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. Eur J Hum Genet 2000, 8(10):793-796.
92. Disset A., Bourgeois C.F., Benmalek N., et al. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. Hum Mol Genet 2006, 15(6):999-1013.
93. Gangopadhyay S.B., Sherratt T.G., Heckmatt J.Z., et al. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am J Hum Genet 1992, 51(3):562-570.
94. Winnard A.V., Mendell J.R., Prior T.W., et al. Frameshift deletions of exons 3-7 andrevertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am J Hum Genet 1995, 56(1):158-166.
95. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. JClin Invest 2009, 119(6):1583-1594.
96. Bello L., Piva L., Barp A., et al. Importance of SPP1 genotype as a covariate inclinical trials in Duchenne muscular dystrophy. Neurology 2012, 79(2):159-162.
97. Pegoraro E., Hoffman E.P., Piva L., et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011, 76(3):219-226.
98. Heydemann A., Ceco E., Lim J.E., et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. JClin Invest 2009, 119(12):3703-3712.
99. Flanigan K.M., Ceco E., Lamar K.M., et al. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann Neurol 2013, 73(4):481-488.
100. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9(1):77-93.
101. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9(2):177-189.
102. Bonifati M.D., Ruzza G., Bonometto P., et al. Amulticenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000, 23(9):1344-1347.
103. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991, 41(12):1874-1877.
104. Fenichel G.M., Mendell J.R., Moxley R.T., et al. Acomparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991, 48(6):575-579.
105. Griggs R.C., Moxley R.T., Mendell J.R., et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991, 48(4):383-388.
106. Griggs R.C., Moxley R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993, 43(3 Pt 1):520-527.
107. Manzur A.Y., Kuntzer T., Pike M., et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, (1). CD003725.
108. Wong B.L., Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. JChild Neurol 2002, 17(3):183-190.
109. Moxley R.T., Pandya S., Ciafaloni E., et al. Change in natural history ofDuchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. JChild Neurol 2010, 25(9):1116-1129.
110. Escolar D.M., Hache L.P., Clemens P.R., et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011, 77(5):444-452.
111. Merlini L., Cicognani A., Malaspina E., et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003, 27(2):222-227.
112. Merlini L., Gennari M., Malaspina E., et al. Early corticosteroid treatment in 4Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012, 45(6):796-802.
113. Nigro G., Comi L.I., Politano L., et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26(3):271-277.
114. Cox G.F., Kunkel L.M. Dystrophies and heart disease. Curr Opin Cardiol 1997, 12(3):329-343.
115. Connuck D.M., Sleeper L.A., Colan S.D., et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008, 155(6):998-1005.
116. Viollet L., Thrush P.T., Flanigan K.M., et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012, 110(1):98-102.
117. Takenaka A., Yokota M., Iwase M., et al. Discrepancy between systolic and diastolic dysfunction of the left ventricle in patients with Duchenne muscular dystrophy. Eur Heart J 1993, 14(5):669-676.
118. Giglio V., Pasceri V., Messano L., et al. Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. JAm Coll Cardiol 2003, 42(2):309-316.
119. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005, 116(6):1569-1573.
120. Allen H.D., Flanigan K.M., Thrush P.T., et al. Arandomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. PLoS Curr 2013, 5. pii: ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865.
121. Duboc D., Meune C., Lerebours G., et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. JAm Coll Cardiol 2005, 45(6):855-857.
122. Stollberger C., Finsterer J. Can perindopril delay the onset of heart failure induchenne muscular dystrophy?. JAm Coll Cardiol 2005, 46(9):1781. [author reply: 1782].
123. Corrado G., Lissoni A., Beretta S., et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002, 89(7):838-841.
124. Thrush P.T., Allen H.D., Viollet L., et al. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. Am J Cardiol 2009, 103(2):262-265.
125. Chenard A.A., Becane H.M., Tertrain F., et al. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord 1993, 3(3):201-206.
126. James J., Kinnett K., Wang Y., et al. Electrocardiographic abnormalities in very young Duchenne muscular dystrophy patients precede the onset of cardiac dysfunction. Neuromuscul Disord 2011, 21(7):462-467.
127. Birnkrant D.J., Bushby K.M., Amin R.S., et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010, 45(8):739-748.
128. Eagle M., Baudouin S.V., Chandler C., et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002, 12(10):926-929.
129. Kinali M., Main M., Eliahoo J., et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol 2007, 11(3):160-166.
130. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-termdaily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68(19):1607-1613.
131. Cheuk D.K., Wong V., Wraige E., et al. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2013, (2). CD005375.
132. Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007, 17(6):470-475.
133. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447(7140):87-91.
134. Finkel R.S., Flanigan K.M., Wong B., et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 2013, 8(12):e81302.
135. Du L., Damoiseaux R., Nahas S., et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. JExp Med 2009, 206(10):2285-2297.
136. Kayali R., Ku J.M., Khitrov G., et al. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet 2012, 21(18):4007-4020.
137. Aartsma-Rus A., Fokkema I., Verschuuren J., et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009, 30(3):293-299.
138. Cirak S., Arechavala-Gomeza V., Guglieri M., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011, 378(9791):595-605.
139. Goemans N.M., Tulinius M., van den Akker J.T., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. NEngl J Med 2011, 364(16):1513-1522.
140. Kinali M., Arechavala-Gomeza V., Feng L., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8(10):918-928.
141. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. NEngl J Med 2007, 357(26):2677-2686.
142. Mendell J.R., Rodino-Klapac L.R., Sahenk Z., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013, 74(5):637-647.
143. Mendell J.R., Campbell K., Rodino-Klapac L., et al. Dystrophin immunity in Duchenne's muscular dystrophy. NEngl J Med 2010, 363(15):1429-1437.
144. Wang Z., Storb R., Halbert C.L., et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther 2012, 20(8):1501-1507.